Bristol busy boosting supply of Breyanzi, Abecma as massive Revlimid patent cliff looms Bayer ends work on cough med that passed phase 2b weeks after FDA rejected Merck's drug Magellan Health partners with Zipline to deliver prescriptions by drone Labcorp launches online platform for ordering at-home tests, scheduling in-person appointments UPDATED: Sanofi's flu shots took a back seat to COVID-19 boosters late last year, and major job cuts still loom The hits keep coming: Biogen's Aduhelm marketing, approval under fire in new FTC and SEC probes Resignation galore: Exicure CEO resigns, CTO departs, 3 board members exit after December woes Medicare to cover at-home COVID-19 tests this spring after backlash from lawmakers Tasso, Vault Health team up to provide at-home blood testing for siteless clinical trials Regeneron projects no near-term sales of its blockbuster COVID-19 antibody given FDA action to ground it From Amazon to New Balance, consumer brand execs bring 'outsider' perspective to healthcare Ambu scores FDA clearance for single-use gastroscope and touchscreen display UCB races to regulators after $2.5B rare disease bet delivers data for attack on AstraZeneca and argenx Featured Story | By Eric Sagonowsky With Bristol Myers Squibb only a month away from biopharma's biggest loss of exclusivity this year, industry watchers are eager for any clues about how the company's new and future medicines will perform on the market. The drugmaker has already launched two new CAR-T products, Breyanzi and Abecma, and now it's busy scaling up on the manufacturing front in a bid to meet early demand. read more |
| |
|---|
|
|
| How To Take Your Imaging Trials to the Next Level with Automation Thursday, March 3, 2022 | 11:00 AM ET / 8:00 AM PT Join experts from ICON Medical Imaging and Medidata for this in-depth webinar to learn how to maximize automation on your imaging trial and discuss how automation: Improves the quality of your data for regulatory submission, creates efficiencies to accelerate your trial, and leverages integration to reduce manual steps. Register now. |
Top Stories By Kyle LaHucik Bayer will no longer work on eliapixant, an Evotec-partnered asset that was studied across four indications in midstage tests, including chronic cough. The companies will continue working together on other assets in phase 1, preclinical and discovery stages. read more By Rebecca Torrence Magellan Health plans to roll out a prescription delivery service via drone in partnership with Zipline, starting later this year in North Carolina for specialty and traditional medications. read more By Andrea Park Building on the success of its direct-to-consumer COVID-19 testing options, Labcorp is supplanting its Pixel brand with a new platform that allows it to sidestep healthcare provider middlemen and enable individuals to order their own diagnostic tests. read more By Fraiser Kansteiner While Sanofi's influenza business did gangbusters in Europe for the last three months of the year, the situation was different in the U.S. as the shifting COVID-19 vaccination landscape fueled a meaty sales decline. Meanwhile, Sanofi is still underway with an aggressive effort to slim down—and more cuts are coming in 2022. read more By Fraiser Kansteiner The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen and its troubled Alzheimer’s med, the company revealed in a securities filing Thursday. read more By Kyle LaHucik Chicago biotech Exicure has a lot of soul searching to do as its CEO, chief medical officer, chief technology officer and three board members all hit the exit within a week. The biotech has no assets in human studies and will look to its pacts with Ipsen and AbbVie to save itself from further disaster. read more By Robert King CMS announced a new initiative to cover at-home COVID-19 tests for Medicare beneficiaries starting this spring after a request from Democratic senators. read more By Conor Hale Tasso’s push-button blood collection device attaches to the upper arm and draws a sample from the skin’s capillaries. read more By Kevin Dunleavy After an FDA ruling 11 days ago that banned Regeneron's COVID-19 antibody treatment for use in patients infected by the omicron variant, the company says it doesn't expect to generate any sales of the drug in the first half of 2022. read more By Anastassia Gliadkovskaya Wellforce recently appointed its first ever chief consumer officer. The move comes amid a rising trend in healthcare: executives sourced from outside the industry, and in particular from consumer brands, to lead innovation strategies. read more By Andrea Park The aScope Gastro’s FDA clearance introduces Ambu into the gastroscopy market, comprising approximately 20 million procedures per year to examine a patient’s esophagus, stomach and duodenum. read more By Nick Paul Taylor UCB’s $2.5 billion gamble on Ra Pharmaceuticals has yielded positive phase 3 data. With the rare disease clinical trial hitting its primary endpoint, UCB is preparing to file to join AstraZeneca and argenx in an increasingly congested space. read more |
